2024-11-01 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance vs. S&P 500:**

Merck & Co Inc (MRK) is a pharmaceutical company that develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

* **Cumulative Return:** MRK: 58.97%, VOO (S&P 500): 131.38%
* **Performance Lag:** -72.41% (S&P 500 has outperformed MRK by 72.41%)
* **Relative Divergence:** 13.15% (Current position within the historical range of outperformance vs. S&P 500)

**2. Recent Price Movements:**

* **Closing Price:** 102.32 (Last Market: 102.23)
* **5-Day Moving Average:** 103.82
* **20-Day Moving Average:** 107.53
* **60-Day Moving Average:** 112.83 

**3. Technical Indicators:**

* **RSI:** 24.25 (Signalling oversold territory, potential for a rebound)
* **PPO:** -0.32 (Indicates bearish momentum, but not overly strong)
* **Delta_Previous_Relative_Divergence:** -11.51 (Indicates a recent short-term decline in performance)
* **Expected Return:** 0.0% (Long-term estimated outperformance over S&P 500)

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue       |
|--------------|-------|----------------|
| 2024-08-05  | 2.15  | $16.11 B      |
| 2024-05-03  | 1.88  | $15.78 B      |
| 2023-11-03  | 1.87  | $15.96 B      |
| 2023-08-07  | -2.35 | $15.04 B      |
| 2024-08-05  | -2.35 | $15.04 B      |

* **Most Recent Earnings:** The last reported earnings on 2024-08-05 exceeded analysts' expectations, with a strong EPS of 2.15 and revenue reaching $16.11B.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter       | Revenue     | Profit Margin |
|---------------|-------------|---------------|
| 2024-06-30  | $16.11B    | 76.76%        |
| 2024-03-31  | $15.78B    | 77.56%        |
| 2023-12-31  | $14.63B    | 73.26%        |
| 2023-09-30  | $15.96B    | 73.29%        |
| 2023-06-30  | $15.04B    | 73.24%        |

**2) Capital and Profitability:**

| Quarter       | Equity     | ROE       |
|---------------|------------|------------|
| 2024-06-30  | $43.58B   | 12.52%      |
| 2024-03-31  | $40.36B   | 11.80%      |
| 2023-12-31  | $37.58B   | -3.26%      |
| 2023-09-30  | $41.25B   | 11.50%      |
| 2023-06-30  | $38.69B   | -15.44%     |

* **Financial Highlights:** Merck shows consistent revenue growth and strong profitability across recent quarters. However, ROE has fluctuated, likely due to factors like acquisitions or changes in capital structure.

**6. News and Recent Issues:**

* **Recent Earnings News:** The latest earnings release on August 5th, 2024, was well received by analysts and investors, with a positive impact on the stock price.
* **Market Outlook:** Several analysts remain optimistic about Merck's future due to the company's strong financial performance and promising pipeline of new products.
* **Analyst Opinions:** FINBOLD reported consensus BUY ratings from several reputable analysts, highlighting the company's strong fundamentals and growth potential.

**7. Overall Analysis:**

Merck & Co Inc (MRK) presents a mixed picture. While the company boasts impressive financial performance, strong product development, and a positive market outlook, its recent stock performance has lagged behind the S&P 500. However, technical indicators suggest oversold conditions, potentially indicating a rebound.  The company's long-term growth prospects are promising, making it a potential investment for long-term investors seeking exposure to the pharmaceutical sector.

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. 
